| pubmed-article:9171326 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9171326 | lifeskim:mentions | umls-concept:C0012655 | lld:lifeskim |
| pubmed-article:9171326 | lifeskim:mentions | umls-concept:C0031809 | lld:lifeskim |
| pubmed-article:9171326 | lifeskim:mentions | umls-concept:C0011923 | lld:lifeskim |
| pubmed-article:9171326 | lifeskim:mentions | umls-concept:C1880018 | lld:lifeskim |
| pubmed-article:9171326 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:9171326 | pubmed:dateCreated | 1997-7-21 | lld:pubmed |
| pubmed-article:9171326 | pubmed:abstractText | In patients with cerebrovascular disease the acetazolamide (ACZ) test is performed to evaluate the decrease in cerebral perfusion pressure (CPP) through the investigation of the vasomotor reactivity (VMR). This latter is currently assessed with ACZ with several methods. Recently, magnetic resonance imaging (MRI) techniques have been developed that are sensitive to stimulus-induced changes in blood flow. Dynamic susceptibility contrast material-enhanced gradient-echo MRI techniques (DSC-MRI) might be an attractive tool to assess VMR. We aimed to test the ability of DSC-MRI in the assessment of VMR. Relative hemodynamic parameters rCBV, MTT, and rCBF were evaluated at baseline after the first injection of gadopentetate dimeglumine and 10 min after the intravenous administration of ACZ (1 g) with a second bolus of contrast agent. Assessment of hemodynamic parameters was performed over the whole hemisphere and also within regions of interest. The significances of the mean differences, before and after ACZ, were assessed with repeated-measures ANOVA with two within factors: laterality (right-left) and ACZ. DSC-MRI with ACZ test was performed in ten healthy controls (aged 51.4+/-16.2 years). The cerebral hemispheric ratio for the three parameters (cerebral blood volume (CBV), mean transit time (MTT), and cerebral blood flow (CBF)) ranged between 1.01 and 1.03. The mean gray matter-to-white matter ratio for CBV, CBF and MTT were 2.44, 2.41 and 1.05, respectively. As the laterality effect was not significant, left and right hemispheric values were averaged. A significant increase of all hemodynamic parameters was observed after ACZ (P<0.01-0.001). The same changes for CBV, CBF and MTT were observed after ACZ according to the regions of interest (P<0.006-0.015). DSC-MRI is a non-invasive method which enables the assessment of VMR. This technique may be added to any conventional MRI in order to detect a hemodynamic impact of an ICA stenosis. Therefore, it might be useful in determining the appropriate management when the indication for surgical versus medical therapy is in question. | lld:pubmed |
| pubmed-article:9171326 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9171326 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9171326 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9171326 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9171326 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9171326 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9171326 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9171326 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9171326 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9171326 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9171326 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9171326 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9171326 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9171326 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:9171326 | pubmed:issn | 0022-510X | lld:pubmed |
| pubmed-article:9171326 | pubmed:author | pubmed-author:PhilipponBB | lld:pubmed |
| pubmed-article:9171326 | pubmed:author | pubmed-author:TrouillasPP | lld:pubmed |
| pubmed-article:9171326 | pubmed:author | pubmed-author:MeyerRR | lld:pubmed |
| pubmed-article:9171326 | pubmed:author | pubmed-author:FromentJ CJC | lld:pubmed |
| pubmed-article:9171326 | pubmed:author | pubmed-author:AdeleinePP | lld:pubmed |
| pubmed-article:9171326 | pubmed:author | pubmed-author:Nighoghossian... | lld:pubmed |
| pubmed-article:9171326 | pubmed:author | pubmed-author:CinottiLL | lld:pubmed |
| pubmed-article:9171326 | pubmed:author | pubmed-author:BerthezeneYY | lld:pubmed |
| pubmed-article:9171326 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9171326 | pubmed:volume | 149 | lld:pubmed |
| pubmed-article:9171326 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9171326 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9171326 | pubmed:pagination | 171-6 | lld:pubmed |
| pubmed-article:9171326 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:9171326 | pubmed:meshHeading | pubmed-meshheading:9171326-... | lld:pubmed |
| pubmed-article:9171326 | pubmed:meshHeading | pubmed-meshheading:9171326-... | lld:pubmed |
| pubmed-article:9171326 | pubmed:meshHeading | pubmed-meshheading:9171326-... | lld:pubmed |
| pubmed-article:9171326 | pubmed:meshHeading | pubmed-meshheading:9171326-... | lld:pubmed |
| pubmed-article:9171326 | pubmed:meshHeading | pubmed-meshheading:9171326-... | lld:pubmed |
| pubmed-article:9171326 | pubmed:meshHeading | pubmed-meshheading:9171326-... | lld:pubmed |
| pubmed-article:9171326 | pubmed:meshHeading | pubmed-meshheading:9171326-... | lld:pubmed |
| pubmed-article:9171326 | pubmed:meshHeading | pubmed-meshheading:9171326-... | lld:pubmed |
| pubmed-article:9171326 | pubmed:meshHeading | pubmed-meshheading:9171326-... | lld:pubmed |
| pubmed-article:9171326 | pubmed:meshHeading | pubmed-meshheading:9171326-... | lld:pubmed |
| pubmed-article:9171326 | pubmed:meshHeading | pubmed-meshheading:9171326-... | lld:pubmed |
| pubmed-article:9171326 | pubmed:meshHeading | pubmed-meshheading:9171326-... | lld:pubmed |
| pubmed-article:9171326 | pubmed:meshHeading | pubmed-meshheading:9171326-... | lld:pubmed |
| pubmed-article:9171326 | pubmed:meshHeading | pubmed-meshheading:9171326-... | lld:pubmed |
| pubmed-article:9171326 | pubmed:meshHeading | pubmed-meshheading:9171326-... | lld:pubmed |
| pubmed-article:9171326 | pubmed:meshHeading | pubmed-meshheading:9171326-... | lld:pubmed |
| pubmed-article:9171326 | pubmed:meshHeading | pubmed-meshheading:9171326-... | lld:pubmed |
| pubmed-article:9171326 | pubmed:meshHeading | pubmed-meshheading:9171326-... | lld:pubmed |
| pubmed-article:9171326 | pubmed:meshHeading | pubmed-meshheading:9171326-... | lld:pubmed |
| pubmed-article:9171326 | pubmed:year | 1997 | lld:pubmed |
| pubmed-article:9171326 | pubmed:articleTitle | Assessment of cerebrovascular reactivity by dynamic susceptibility contrast-enhanced MR imaging. | lld:pubmed |
| pubmed-article:9171326 | pubmed:affiliation | Department of Neurology Cerebrovascular Disease and Ataxia Research Center, Neurological Hospital, Lyon, France. | lld:pubmed |
| pubmed-article:9171326 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9171326 | lld:pubmed |
